Breaking Finance News

A report released today by Zacks Investment Research about Flex Pharma Inc (NASDAQ:FLKS) raises the target price to $7.00

Yesterday Flex Pharma Inc (NASDAQ:FLKS) traded -1.28% lower at $6.23. The company’s 50-day moving average is $6.69 and its 200-day moving average is $10.24. The last closing price is down -39.95% from the 200-day moving average, compared to the S&P 500 which has decreased -0.03% over the same time. 41,016 shares of the stock were exchanged, down from an average trading volume of 80,133

Flex Pharma Inc (NASDAQ:FLKS) had its target price raised to $7.00 by Zacks Investment Research in a report released 11/30/2016. The new target price indicates a possible upside of 0.12% based on the company's last closing price.

See Chart Below

Flex Pharma Inc (NASDAQ:FLKS)

Flex Pharma Inc has a 52 week low of $4.55 and a 52 week high of $13.97 The company’s market cap is currently $0.

In addition to Zacks Investment Research reporting its target price, a total of 6 brokers have issued a report on the stock. The consensus target price is $27.00 with 1 broker rating the stock a strong buy, 5 brokers rating the stock a buy, 0 brokers rating the stock a hold, 0 brokers rating the stock a underperform, and finally 0 brokers rating the stock a sell.

General Information About Flex Pharma Inc (NASDAQ:FLKS)

Flex Pharma, Inc. is a biotechnology company. The Company develops treatments for nocturnal leg cramps, muscle cramps and spasms associated with severe neuromuscular conditions, and exercise associated muscle cramps (EAMCs). The Company's product candidates activate certain receptors in primary sensory neurons, which then act through neuronal circuits to reduce the repetitive firing, or hyperexcitability, of alpha-motor neurons in the spinal cord, thereby preventing or reducing the frequency and intensity of muscle cramps and spasms. The Company operates through developing and commercializing products for nocturnal leg cramps, muscle cramps, spasms and spasticity associated with severe neuromuscular conditions, and exercise-associated muscle cramps segment. The Company's lead drug product candidate is FLX-787, which is in the Phase II clinical trial stage. It is developing a consumer brand and products specifically formulated to treat athletes suffering from EAMCs.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.